报价延迟最少15分钟:2026/04/21 22:31 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
38.9 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.95/-4.98
|
|
企业价值
4.26B
|
| 资产负债 |
|
每股账面净值
9.48
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
7.70M
|
|
每股收益
0.05
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors. |
